Orca Wealth Management LLC Invests $4.53 Million in AstraZeneca PLC (NASDAQ:AZN)

Orca Wealth Management LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 69,166 shares of the company’s stock, valued at approximately $4,532,000. AstraZeneca accounts for about 4.1% of Orca Wealth Management LLC’s investment portfolio, making the stock its 5th largest holding.

A number of other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC raised its stake in shares of AstraZeneca by 112.4% in the 2nd quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock valued at $1,067,000 after acquiring an additional 7,241 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of AstraZeneca by 39.1% in the second quarter. The Manufacturers Life Insurance Company now owns 206,446 shares of the company’s stock valued at $16,104,000 after purchasing an additional 58,039 shares in the last quarter. Creative Planning grew its holdings in shares of AstraZeneca by 18.3% in the second quarter. Creative Planning now owns 208,059 shares of the company’s stock valued at $16,227,000 after purchasing an additional 32,132 shares in the last quarter. Magnolia Capital Advisors LLC acquired a new position in shares of AstraZeneca in the second quarter valued at approximately $204,000. Finally, NewEdge Advisors LLC grew its holdings in shares of AstraZeneca by 13.2% in the second quarter. NewEdge Advisors LLC now owns 49,589 shares of the company’s stock valued at $3,867,000 after purchasing an additional 5,779 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Down 0.7 %

Shares of NASDAQ:AZN opened at $69.59 on Wednesday. The company has a market capitalization of $215.80 billion, a PE ratio of 33.30, a P/E/G ratio of 1.13 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The firm has a 50 day simple moving average of $66.58 and a 200-day simple moving average of $74.08.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the firm earned $0.87 EPS. The company’s revenue was up 18.0% compared to the same quarter last year. On average, equities analysts predict that AstraZeneca PLC will post 4.12 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.